Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx Corp's majority-owned subsidiary RXi Pharmaceuticals has secured a worldwide non-exclusive license from Cold Spring Harbor Laboratory to their short hairpin RNAi technology (shRNAi).
Subscribe to our email newsletter
The licensed technology potentially allows for the more efficient triggering of RNA interference (RNAi) and includes the use of shRNAis either delivered as RNA compositions or encoded by DNA constructs. Patents covering this technology are currently pending. Financial terms were not disclosed for competitive reasons.
“With this license for all human therapeutic areas, we gain the well-validated advantage of shRNAi – which is reported to be up to 10- to 100-fold more potent compared with standard siRNA,” said Tod Woolf, RXi’s president and CEO.